Clinical trial
Comparison of the Therapeutic Potential of Autologous Bone Marrow Mononuclear Cells Versus Allogenic Wharton Jelly-derived Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb-threatening Ischemia
NCT05631444 is registered in ClinicalTrials.gov with Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Comparison of the Therapeutic Potential of Autologous Bone Marrow Mononuclear Cells Versus Allogenic Wharton Jelly-derived Mesenchymal Stem Cells in Diabetic Patients With Chronic Limb-threatening Ischemia
- Lead sponsor
- Fundación Oftalmológica de Santander Clínica Carlos Ardila Lulle
- Phase
- Phase 1/2
- Overall status
- Completed
- Start date
- January 1, 2019
- Completion date
- October 28, 2022
- Enrollment
- 24 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.